INTRODUCCION

HOMEOPHATY WAS INITIATED IN THE XVIII CENTURY, IT

IS, MORE THAN 200 YEARS AGO AND IT WAS BORN IN
GERMANY.
THE HOMEOPHATIC PHARMACY HAS NOWADAYS
MORE THAN 3000 RECOGNIZED PRODUCTS
FROM THE VEGETAL, MINERAL AND ANIMAL
KINGDOMS.
THEY ARE USED IN TREATMETS OF ACUTE
AND CHRONIC DISEASES IN HUMANS.

Countries leading the Homeophatic Market

Continents
United
States of
America
Europ
France
India
Asia
Germany
Europ

England
Spain
Holland
Italy
Brasil
Argentina
Chile
Mexico

Europ
Europ
Europ
Europ
America
America
America
America

750 Million Eur.

405 Million Eur.
390 Million Eur
270 Million Eur.

70 % DEL COMERCIO ESTA EN EUROPA.

Statystical data 2010

Results of the application

of VIDATOX 30 CH in
patients

Author: M. Sc. Fabio Linares Pazos.

VIDATOX 30 CH

How it is obtained?

How it works?

How it is administered?

CERTIFICATE OF SANITARY
REGISTRATION OF THE PRODUCT
CECMED-CUBA

Introduction

Early diagnostic, surgery, chemotherapy, radiotherapy

and therapeutic vaccines are the main weapons for
cancer treatment in Conventinal Medicine.
The goals of conventional treatments are:
-Improvement of the quality of life
-To Increase the survival of the patients.
-To avoid the recurrence of malignant tumours
(metastasis).

Oncologic family and treatmets prescribed

Group 1

Group 2

Affected organs and neoplasic family

Most frecuent symptoms depending upon the affected organ.

Lungs (Respiratory difficulty, thoracic pain, cough, aggravation of symptoms by
effort, anorexia, weight loss)
Prostate gland (Difficulty when urinating, pain, hematuria, difficulty to defecate,
anorexia, weight loss)
Colon (Pain, constipation, difficulty to defecate, diarrheas, bleeding, anorexia)
Breasts (Pain, the general health taken, cough, respiratory difficulty)
Uterus (Pain, vaginal secretion, inflammation, bleeding)
Lymphoid tissue ( Hematological upsets, anemia, respiratory
difficulty when swallowing solids)

difficulty,

Pancreas (Inflammation, anemia, jaundice, increase of glucemia)

Brain (Weakness in extremities, vision's decrease, difficulty when talking,
difficulty when swallowing solids)

PATIENTS REPORTING IMPROVEMENT IN THE EVOLUTIVE

STUDIES

SEX

MONTHS

Age

Total

12

> 1 year

<60

56

34

90

17

27

14

60-64

10

15

25

10

65-69

14

70-74

12

20

75-80

12

>80

13

Total

92

82

174

30

54

25

12

13

90 patients(64.6%)GROUP 1
19 patients (54,5%) GROUP 2

Improvement in 3-9 months treatmet

ANALGESIC EFFECT AFTER

30 DAYS OF TREATMENT

Pain status

Before
treatment

1 month After
treatment

17

27%

19

30%

39

62%

39

62%

8%

8%

3%

63

63

IN 65.98 % OF THE PATIENTS WAS

REPORTED INCREASED PAIN RELIEF
Nota: Pain status established according to metodology published by the Hematology and
orthopedic services from " Hermanos Ameijeiras Cuban Hospital

CONCLUSSIONS
Relieve of the pain.
Reduction of the inflammatory processes
Improvement of the Quality of life
Increasing in survival
Absence of side effects

VIDATOX 30 CH
THEREHASBEENREPORTED
EXPONENTIALINCREASEINTHE
INTAKEOFTHEPRODUCTDUETO
PATIENTSOWNDESIRE.
TODAYTHEPRODUCTISBEING
ADMINISTEREDTOMORETHAN65000
PATIENTSFROMMANYCOUNTRIES,AMONG
THEM:ITALY,USA,MEXICO,CHILE,
COLOMBIA,ARGENTINA,GREECE,SPAIN,
PORTUGALANDCHINA.